《护士健康研究 II 中血浆 25-羟维生素 D 与乳腺癌风险》。
Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II.
机构信息
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
出版信息
Breast Cancer Res. 2011 May 11;13(3):R50. doi: 10.1186/bcr2880.
INTRODUCTION
Experimental evidence indicates vitamin D may play an important role in breast cancer etiology but epidemiologic evidence to date is inconsistent. Vitamin D comes from dietary intake and sun exposure and plasma levels of 25-hydroxyvitamin D (25(OH)D) are considered the best measure of vitamin D status.
METHODS
We conducted a prospective nested case-control study within the Nurses' Health Study II (NHSII). Plasma samples collected in 1996 to 1999 were assayed for 25(OH)D in 613 cases, diagnosed after blood collection and before 1 June 2007, and in 1,218 matched controls. Multivariate relative risks (RR) and 95% confidence intervals (CI) were calculated by conditional logistic regression, adjusting for several breast cancer risk factors.
RESULTS
No significant association was observed between plasma 25(OH)D levels and breast cancer risk (top vs. bottom quartile multivariate RR = 1.20, 95% CI (0.88 to 1.63), P-value, test for trend = 0.32). Results were similar when season-specific quartile cut points were used. Results did not change when restricted to women who were premenopausal at blood collection or premenopausal at diagnosis. Results were similar between estrogen receptor (ER)+/progesterone receptor (PR)+ and ER-/PR- tumors (P-value, test for heterogeneity = 0.51). The association did not vary by age at blood collection or season of blood collection, but did vary when stratified by body mass index (P-value, test for heterogeneity = 0.01).
CONCLUSIONS
Circulating 25(OH)D levels were not significantly associated with breast cancer risk in this predominantly premenopausal population.
简介
实验证据表明，维生素 D 可能在乳腺癌发病机制中发挥重要作用，但迄今为止的流行病学证据并不一致。维生素 D 来自饮食摄入和阳光照射，而血浆 25-羟维生素 D（25（OH）D）水平被认为是衡量维生素 D 状况的最佳指标。
方法
我们在护士健康研究 II（NHSII）中进行了一项前瞻性巢式病例对照研究。1996 年至 1999 年采集的血浆样本在 613 例病例中进行了 25（OH）D 检测，这些病例在采血后和 2007 年 6 月 1 日前被诊断出，同时还在 1218 名匹配的对照中进行了检测。多变量相对风险（RR）和 95%置信区间（CI）通过条件逻辑回归计算，调整了几个乳腺癌危险因素。
结果
血浆 25（OH）D 水平与乳腺癌风险之间未观察到显著关联（最高与最低四分位距多变量 RR = 1.20，95%CI（0.88 至 1.63），P 值，趋势检验 = 0.32）。使用季节特异性四分位点时，结果相似。当限制在采血时或诊断时为绝经前的女性时，结果没有改变。在雌激素受体（ER）+/孕激素受体（PR）+和 ER-/PR-肿瘤之间，结果相似（P 值，异质性检验 = 0.51）。该关联不受采血时的年龄或采血季节的影响，但当按体重指数分层时，结果有所不同（P 值，异质性检验 = 0.01）。
结论
在这个主要为绝经前的人群中，循环 25（OH）D 水平与乳腺癌风险无显著相关性。
Zotero 插件